Document is current
Any future updates will be listed below
-
Authors
Tsai, Hsin-Yi
Tsai, Kuen-Jang
Wu, Deng-Chyang
Huang, Yaw-Bin
Lin, Ming-Wei https://orcid.org/0000-0002-8880-5473
-
Funding
Funding for this research was provided by:
E-Da Hospital (EDCHS113002; EDCHJ112002; ECPJ111007; EDPJ110009; EDPJ112031; EDPJ111038; EDPJ110041)
Ministry of Science and Technology, Taiwan (MOST-110-2314-B-650-006)
Kaohsiung Medical University (KMU-TC112A02, M112015)
- License Information
-
More Information
Article History
Received: 1 August 2024
Accepted: 11 February 2025
First Online: 23 February 2025
Declarations
:
: The studies involving animal participants were reviewed and approved by Institutional Animal Care and Use Committee (IACUC) of E-Da Hospital. The approved project: The application of mitochondrial cell therapy in gastric cancer treatment. (Approval number: IACUC-EDAH-112015; date of approval: 2023/8/1-2025/7/31). The human gastric cancer cell line AGS was purchased from ATCC, under a Material Transfer Agreement (). The human gastric cancer cell line MKN45 cell was purchased from DSMZ, under a Material Transfer Agreement (). The human normal gastric epithelial cell line GES-1 cell was obtained through Cytion (Cell Lines Service, Eppelheim, Germany), under a Material Transfer Agreement (). The original source has confirmed that there was initial ethical approval for the collection of human cells, and that the donors had signed informed consent.
: The authors declare that they have not used Artificial Intelligence in this study.
: Not applicable.
: The authors declare no conflict of interest.
